Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting

CAMBRIDGE, Mass. & MONTREAL–(Small business WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a foremost medical-phase precision oncology business, these days declared it has been selected for an oral presentation of medical knowledge from its ongoing Phase 1/2 TRESR (Procedure Enabled by SNIPRx) demo of RP-3500, a powerful and selective oral smaller molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-associated protein kinase), as well as two further poster presentations at the approaching 2022 AACR Once-a-year Assembly held in New Orleans on April 8-13, 2022.

The Enterprise also declared that it will host a conference phone with accompanying slides for analysts and investors on Monday, April 11, 2022 at 6:30 p.m. Japanese Time. The simply call and presentation will involve RP-3500 information introduced at the 2022 AACR Annual Assembly as properly as more data, representing an update from details in the Company’s abstract (referenced down below), which displays an before slash-off date.

“As with any new therapeutic class, differentiation amid early solution candidates is what eventually decides results in the clinic and a route toward registration,” commented Lloyd M. Segal, President and Main Govt Officer of Repare. “In the context of knowledge released as not long ago as currently, we are self-confident that RP-3500 is a really differentiated and possibly leading ATR inhibitor. We proceed to attract on a prosperity of knowledge from the detailed Stage 1 monotherapy module of our Section 1/2 TRESR demo of RP-3500 to start setting up its therapeutic likely. We look forward to seeing these info presented at AACR and talking about RP-3500’s ongoing and long term enhancement ideas.”

Oral Presentation Details on RP-3500 Period 1/2 TRESR Demo Benefits:

Title: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-similar inhibitor (ATRi), in sufferers (pts) with DNA problems maintenance (DDR) decline-of-operate (LOF) mutant tumors in the Section 1/2 TRESR trial

Presenter: Dr. Timothy Yap, MBBS, Ph.D., FRCP, Health-related Director, Institute for Used Most cancers Science, Affiliate Professor, Division of Investigational Most cancers Therapeutics, Division of Most cancers Medicine, MD Anderson Cancer Centre, Houston, Texas

Abstract Number: CT030

Session Title: Clinical Trials Minisymposium – Affected person Choice Tactics for Molecularly Specific Agents in Scientific Trials

Date/ Time: Monday, Apr 11, 2022 at 3:05 PM – 3:15 PM CT

Poster Presentation Facts on SNiPDx Panel for Artificial Deadly Drug Discovery:

Title: Detection of biallelic reduction of DNA fix genes in formalin-fixed, paraffin embedded (FFPE) tumor samples applying a novel tumor-only sequencing panel with mistake correction

Presenter: Dominik Glodzik, Ph.D., Repare Therapeutics, Instructor in Biomedical Informatics, Harvard Professional medical Faculty

Summary Number: 2801

Session Title: Diagnostic Biomarkers

Date/ Time: Tuesday, April 12, 2022 at 9:00 AM CT

Poster Specifics on Preclinical Details for PKMYT1 Inhibitor RP-6306:

Title: RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in mix with gemcitabine in CCNE1 amplified cancer cells

Presenter: Jimmy Fourtounis, Repare Therapeutics

Summary Number: 5650

Session Title: Mobile Cycle

Date/ Time: Friday, April 8, 2022 at 12:00 – 1:00 PM CT

Firm Conference Simply call:

The Business will host a conference call with accompanying slides for analysts and investors on Monday, April 11, 2022 at 6:30 p.m. Japanese Time to even further explore the RP-3500 data presented at the 2022 AACR Annual Assembly. Repare’s govt administration workforce will be joined by Timothy Yap, MBBS, PhD, FRCP, Principal Investigator and Professional medical Director, Institute for Applied Cancer Science, Affiliate Professor, Division of Investigational Cancer Therapeutics, Division of Most cancers Medication, MD Anderson Cancer Center, Houston, TX.

To entry the get in touch with, be sure to dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (worldwide) at minimum 10 minutes prior to the begin time and inquire to be joined to the Repare Therapeutics contact. A dwell online video webcast will be accessible in the Trader segment of the Company’s site at A webcast replay will also be archived for at least 30 days.

About Repare Therapeutics’ SNIPRx® Platform

Repare’s SNIPRx® system is a genome-huge CRISPR-primarily based screening tactic that makes use of proprietary isogenic mobile lines to discover novel and identified synthetic lethal gene pairs and the corresponding patients who are most very likely to profit from the Company’s therapies based on the genetic profile of their tumors. Repare’s system permits the improvement of precision therapeutics in clients whose tumors incorporate a single or far more genomic alterations discovered by SNIPRx® screening, in buy to selectively focus on people tumors in sufferers most most likely to reach clinical gain from ensuing product or service candidates.

About Repare Therapeutics, Inc.

Repare Therapeutics is a main scientific-phase precision oncology corporation enabled by its proprietary artificial lethality technique to the discovery and development of novel therapeutics. The Enterprise utilizes its genome-huge, CRISPR-enabled SNIPRx® system to systematically uncover and acquire really focused cancer therapies targeted on genomic instability, which include DNA destruction repair. The Company’s pipeline contains its guide products candidate RP-3500, a possible foremost ATR inhibitor at present in Stage 1/2 scientific progress, its next medical prospect, RP-6306, a PKMYT1 inhibitor at present in Section 1 medical advancement, a Polθ inhibitor plan, as effectively as eight other early-stage, pre-clinical systems. For more information and facts, be sure to stop by

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

Ahead-Searching Statements

This push release contains “forward-wanting statements” within just the meaning of the Personal Securities Litigation Reform Act of 1995. All statements in this press launch other than statements of historical information are “ahead-seeking statements. These statements may be recognized by words and phrases these as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variants of these words or equivalent expressions that are supposed to identify forward-looking statements, whilst not all forward-looking statements incorporate these phrases. Ahead-seeking statements in this press launch consist of, but are not confined to, statements regarding the clinical growth of the Company’s pipeline and its research and improvement programs, which includes the anticipated timing, anticipated individual enrollment, demo results or affiliated expenses of its Section 1/2 TRESR scientific demo of RP-3500. These ahead-looking statements are centered on the Company’s expectations and assumptions as of the date of this press release. Every of these ahead-looking statements will involve pitfalls and uncertainties that could induce the Company’s clinical development systems, foreseeable future results or overall performance to differ materially from those people expressed or implied by the ahead-on the lookout statements. Quite a few things could induce dissimilarities in between current expectations and actual success, including the impacts of the COVID-19 pandemic on the Company’s organization, clinical trials and economic position, unexpected security or efficacy data observed during preclinical research or clinical trials, scientific trial web page activation or enrollment rates that are lessen than anticipated, modifications in predicted or existing competitiveness, variations in the regulatory environment, the uncertainties and timing of the regulatory approval course of action, and unexpected litigation or other disputes. Other things that may trigger the Company’s actual results to vary from those expressed or implied in the forward-on the lookout statements in this push release are identified in the section titled “Risk Things” in the Company’s Annual Report on Variety 10-K for the year ended December 31, 2021 submitted with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers (“AMF”) on March 1, 2022, and its other files subsequently filed with or furnished to the SEC and AMF. The Company expressly disclaims any obligation to update any ahead-wanting statements contained herein, no matter if as a outcome of any new data, potential gatherings, improved instances or usually, besides as otherwise needed by legislation.